What did UBS change in its NEO analyst rating on Feb 18, 2026?

UBS maintained a **Hold** on NeoGenomics, Inc. (NEO) on February 18, 2026. There was no upgrade, downgrade, or new price target. The note kept UBS’s neutral stance and produced a small market reaction.

How should investors interpret a maintained Hold in the NEO analyst rating?

A maintained Hold in the NEO analyst rating signals neutrality. Investors should monitor fundamentals like test volume and margins. Short-term traders may trim positions, while longer-term holders focus on execution and guidance updates.

Did UBS provide a new NEO price target with the rating?

No. UBS did not publish a new NEO price target on February 18, 2026. Because of that, consensus targets remain based on earlier analyst models until firms issue updates.

What is Meyka’s view after the UBS note on the NEO analyst rating?

Meyka AI rates NEO with a grade of **B**. We factor in S&P 500 comparison, sector results, growth, key metrics, and analyst consensus. Use the grade with other research; it is not financial advice.

Analyst Ratings

UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026

ByHuzaifa Zahoor February 19, 2026

UBS maintained a Hold rating on NeoGenomics, Inc. (NEO) on February 18, 2026. The NEO analyst rating stayed unchanged in UBS’s note, and the market registered a short-term pullback of -1.54% (-$0.16) following the mention. We review the UBS action, the lack of a new price target, and what this NEO analyst rating means for investors looking at diagnostics and lab services.